Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360698 · ClinicalTrials.gov registry record · Phase 4
Insulin Glulisine in Type 2 Diabetic Patients
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 106
- Enrollment target
NCT00360698 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 106 participants.
The verdict
NCT00360698, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 106 participants
- Enrollment target
Study Summary
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.
Interventions
- DRUG Metformin
- DRUG Insulin Glargine
- DRUG Glimepiride
- DRUG Insulin Glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360698
The ClinicalTrials.gov registry entry for NCT00360698 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT00360698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00360698 about?
NCT00360698 is a clinical study titled "Insulin Glulisine in Type 2 Diabetic Patients". To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.
What is the current status of trial NCT00360698?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 106 participants. The study started on 2006-07. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00360698?
The interventions under investigation include: Metformin (DRUG), Insulin Glargine (DRUG), Glimepiride (DRUG), Insulin Glulisine (DRUG).
Who is sponsoring clinical trial NCT00360698?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.